A trial for an experimental drug that could potentially serve as treatment for coronavirus has shown encouraging results.
On Saturday, Cedars-Sinai Hospital announced that 68% of COVID-19 patients hospitalized with severe complications exhibited an improvement after being administered the experimental antiviral drug remdesivir, reported NBC Los Angeles.
While remdesiver has not been approved by the FDA, the therapy was given under the “compassionate use” program which allows for experimental drugs to be given to patients with life-threatening conditions when no other treatment exists.
The small trial consisted of 53 patients across the United States, Canada, Europe and Japan.
"Currently there is no proven treatment for COVID-19. We cannot draw definitive conclusions from these data, but the observations from this group of hospitalized patients who received remdesivir are hopeful," said Dr. Jonathan Grein, director of epidemiology at Cedars. "We look forward to the results of controlled clinical trials to potentially validate these findings."
The clinical trial is being sponsored by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health.